If you’re eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL), now’s the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, “Not so fast.” While the biotech is undeniably ascendant after getting its first medicine approved for sale in mid-March, the pharma juggernaut […]